What It Takes to Support Emerging Biopharma Programs Through Rapid Candidate Identification

Sponsored by Catalent

In biologics development, there is a constant tension between moving quickly and making the right decisions early. As programs progress toward the clinic, early cell line development plays a central role in shaping not just timelines, but also scalability, consistency, and overall program confidence.

In this discussion, Laura Daley, PhD, Senior Director of Cell Biology & Process Development at Catalent Pharma Solutions, explains how expectations in emerging biopharma are evolving. While speed is still important, there is a growing emphasis on reducing risk earlier in development and gaining better insight into manufacturability, scalability, and product quality at the outset.

A key theme is the increasing complexity of biologic modalities. Teams are no longer focused solely on traditional monoclonal antibodies, but also on more complex molecules such as bispecifics and other engineered formats. This shift requires development approaches that can handle variability in gene expression and support optimization of more intricate molecular designs.

The discussion also highlights the value of generating earlier, more actionable data during cell line development. Technologies like GPEx® Lightning support this by enabling earlier insight into expression levels and product quality, helping teams evaluate candidates more effectively and make more informed decisions about which programs to advance.

Another important point is the need for continuity across development and manufacturing. As timelines remain compressed, reducing unnecessary handoffs and maintaining process consistency becomes increasingly important to help ensure predictability as programs scale.